Valuation: Ionis Pharmaceuticals, Inc.

Market Cap 13.75B 12.03B 11.09B 10.28B 19.51B 1,305B 19.82B 133B 51.7B 644B 51.61B 50.49B 2,226B P/E 2026 *
-23.2x
P/E 2027 * -65.9x
Enterprise Value 13.49B 11.81B 10.88B 10.09B 19.15B 1,281B 19.46B 130B 50.75B 632B 50.66B 49.56B 2,185B EV / Sales 2026 *
15.1x
EV / Sales 2027 * 9.09x
Free-Float
99.09%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ionis Pharmaceuticals, Inc.

1 day+3.49%
1 week+8.40%
Current month+8.40%
1 month+16.88%
3 months+16.32%
6 months+3.34%
Current year+8.65%
1 week 77.95
Extreme 77.95
86.67
1 month 72.3
Extreme 72.3
86.67
Current year 68.9
Extreme 68.9
86.74
1 year 40.03
Extreme 40.03
86.74
3 years 23.95
Extreme 23.95
86.74
5 years 23.95
Extreme 23.95
86.74
10 years 23.9
Extreme 23.9
86.74
Manager TitleAgeSince
Investor Relations Contact 60 2012-06-30
Chief Executive Officer 64 2019-12-31
Director of Finance/CFO 64 2000-04-30
Director TitleAgeSince
Director/Board Member 64 2005-12-12
Director/Board Member 73 2002-04-30
Director/Board Member 64 2019-03-24
Date Insider Type Main position Quantity % Market Cap.
06-25Sell

General Counsel

-3,069 0.0019%
06-25Fiscal year

Founder

150,000 0.0908%
06-25Fiscal year

Chief Operating Officer

78,000 0.0472%
Change 5-day change 1-year change 3-year change Capi.($)
+3.51%+8.40%+105.72%+105.72% 13.75B
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.39%+1.52%+418.46%+620.42% 40.39B
+0.74%+7.38%+27.71%-4.31% 34.38B
-0.85%+7.52%+27.14%+61.64% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.12%+0.37% - - 16.64B
-3.27%+3.14%+71.28%+131.91% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
-1.63%+9.78%+1,764.71%+697.48% 12.69B
Average -0.01%+8.75%+270.82%+186.40% 25.87B
Weighted average by Cap. +0.00%+6.58%+182.87%+169.91%

Financials

2026 *2027 *
Net sales 893M 782M 720M 668M 1.27B 84.77B 1.29B 8.64B 3.36B 41.84B 3.35B 3.28B 145B 1.5B 1.31B 1.21B 1.12B 2.13B 143B 2.17B 14.53B 5.65B 70.37B 5.64B 5.52B 243B
Net income -595M -521M -480M -445M -845M -56.51B -859M -5.76B -2.24B -27.89B -2.24B -2.19B -96.4B -199M -174M -160M -148M -282M -18.84B -286M -1.92B -747M -9.3B -745M -729M -32.15B
Net Debt -252M -221M -204M -189M -358M -23.96B -364M -2.44B -950M -11.83B -948M -927M -40.88B -88.41M -77.36M -71.3M -66.08M -125M -8.39B -127M -855M -332M -4.14B -332M -325M -14.31B
Logo Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.
Employees
1,402
Date Price Change Volume
26-07-07 US$85.99 +3.38% 1,869,701
26-07-06 US$83.18 +1.69% 1,847,437
26-07-02 US$81.80 +3.30% 2,301,899
26-07-01 US$79.19 -0.13% 1,442,398
26-06-30 US$79.29 -1.74% 2,380,302
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
83.18USD
Average target price
104.86USD
Spread / Average Target
+26.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IONS Stock